RecruitingModerate-to-severe Plaque Psoriasis
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Eligible age
19+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Adult participants ≥19 years of age
- ✓ Diagnosis of moderate-to-severe plaque psoriasis
- ✓ Candidate for phototherapy or systemic therapy
- ✓ Will begin deucravacitinib according to approved product label
You may not qualify if…
- ✕ Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
- ✕ Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)
Source: ClinicalTrials.gov · NCT06258668 · last updated 2024-11-06